Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational studyLeticia Monin, Sheeba Irshad, Miguel Muñoz‐Ruiz et al.|The Lancet Oncology|2021Cited by 614